Advisory Research’s Blueprint Medicines BPMC Stock Holding History

Advisory Research’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-19,400	Closed	-$1.79M	–	183
2023 Q4	$1.79M	Buy	19,400 +15,068	+348%	+$976K	0.28%	95
2023 Q3	$218K	Buy	+4,332	New	+$231K	0.03%	413
2018 Q2	–	Sell	-13,834	Closed	-$1.27M	–	371
2018 Q1	$1.27M	Sell	13,834 -7,646	-36%	-$659K	0.02%	251
2017 Q4	$1.62M	Buy	21,480 +4,415	+26%	+$311K	0.03%	240
2017 Q3	$1.19M	Sell	17,065 -10,072	-37%	-$538K	0.02%	280
2017 Q2	$1.38M	Buy	+27,137	New	+$1.15M	0.02%	278

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisory Research's BPMC Position: Q1 2024 in Review

Advisory Research sold out of Blueprint Medicines (BPMC) in Q1 2024, closing a stake of 19,400 shares — an estimated $1.79M sold.

Advisory Research first reported a position in BPMC in Q2 2017 and held it in 6 quarters. The position peaked at $1.79M in Q4 2023. 283 funds tracked by Wall St. Rank hold BPMC as of Q1 2024.

Advisory Research reported no remaining Blueprint Medicines position as of Q1 2024 after selling out during the quarter.
Advisory Research sold 19,400 Blueprint Medicines shares in Q1 2024, an estimated $1.79M.
Advisory Research first reported a position in Blueprint Medicines in Q2 2017 and held it in 6 quarters.
Advisory Research's Blueprint Medicines position peaked at $1.79M in Q4 2023.
283 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2024.

Based on Advisory Research's 13F filing for Q1 2024, filed 14 May 2024.